Bevacizumab-tnjn (Avzivi)
Dilution requiredFull monograph review pending
U.S. label preparation
Avzivi · Dilution required
- Preparation
- Dilute the calculated dose from the 25 mg/mL IV vial to a total of 100 mL with 0.9% sodium chloride. Avoid dextrose-containing solutions.
- Administration and handling
- Give the first infusion over 90 minutes. If tolerated, the second may run over 60 minutes, then subsequent infusions over 30 minutes if the second was tolerated.
Product and source details
Bio-Thera Solutions, Ltd. · BLA761198
FDA labeling action 2023-12-06. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.